Long-term Follow-Up of Serum Immunoglobulin Levels in Blinatumomab-Treated Patients With Minimal Residual Disease-Positive B-precursor Acute Lymphoblastic Leukemia

Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64.

Abstract

No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bispecific / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulins / blood*
  • Male
  • Neoplasm, Residual
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / blood
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

  • Antibodies, Bispecific
  • Antineoplastic Agents
  • Immunoglobulins
  • blinatumomab

Associated data

  • ClinicalTrials.gov/NCT00560794